腹腔镜子宫肌瘤剔除术同期宫腔镜检查不增加感染风险:NSQIP分析
基于ACS NSQIP数据库2015-2023年腹腔镜子宫肌瘤剔除术患者的回顾性队列研究,比较同期宫腔镜检查与单纯肌瘤剔除的术后30天手术部位感染(SSI)和尿路感染(UTI)风险。多因素logistic回归控制年龄、BMI、ASA分级、吸烟、糖尿病、输血、手术时间、住院/门诊、种族及子宫内膜异位症后,同期宫腔镜未显著增加任何SSI、浅表/深部/器官间隙SSI或UTI风险。
要点
- 同期宫腔镜不增加30天任何SSI风险(aOR 0.82, 95%CI 0.56-1.17, p=0.3)。
- 浅表、深部、器官间隙SSI及UTI风险均无显著差异。
- 控制基线合并症和手术复杂度后结论仍稳健。
核心结论
- 控制基线合并症和手术复杂度后,腹腔镜子宫肌瘤剔除术同期宫腔镜检查不显著增加术后30天SSI或UTI风险。
研究设计与样本
- 回顾性队列研究,数据来自美国外科医师学会国家手术质量改进计划(ACS NSQIP)数据库2015-2023年接受腹腔镜子宫肌瘤剔除术的患者。
- 主要结局为术后30天任何手术部位感染(SSI),并分别分析浅表、深部及器官间隙感染;次要结局为术后尿路感染(UTI)。
- 采用多因素logistic回归控制年龄、体重指数、ASA分级、吸烟、糖尿病、输血、手术时间、住院/门诊、种族及子宫内膜异位症。
主要发现
- 同期宫腔镜与任何SSI风险无显著关联(aOR 0.82; 95%CI 0.56-1.17, p=0.3)。
临床怎么用
- 对于有指征的患者,腹腔镜子宫肌瘤剔除术同期行宫腔镜检查不增加术后30天手术部位感染和尿路感染风险,可放心联合实施。
局限性
- 本研究为回顾性数据库分析,可能存在未测量混杂因素。
- 仅评估术后30天感染结局,远期感染风险未涉及。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: We aimed to determine whether hysteroscopy at the time of laparoscopic myomectomy significantly increased the risk of surgical site infection (SSI). DESIGN: A cohort from the American College of Surgeons (ACS) National Surgical Quality Improvement Program (NSQIP) retrospective database. The primary outcome was any surgical site infection within 30 days postoperatively. Further analysis of superficial, deep, and organ space infections was individually performed. Secondary outcome was postoperative urinary tract infection (UTI). Multivariate logistic regression was used to control for other risk factors for surgical site infection. The study was IRB exempt. SETTING: The ACS NSQIP database is a national validated database from academic and community hospitals. PARTICIPANTS: Individuals who had a laparoscopic myomectomy in the years 2015 to 2023. INTERVENTIONS: Laparoscopic myomectomy alone versus laparoscopic myomectomy with concomitant hysteroscopy. MEASUREMENTS AND MAIN RESULTS: The addition of hysteroscopy was not associated with a significant difference in the rates of any SSI (aOR 0.82; 95% CI 0.56-1.17, p = .3), superficial SSI (aOR 0.76, 95% CI 0.48-1.14, p = .2), deep SSI (aOR 1.59, 95 % CI 0.08-10.4, p = .7), organ space SSI (aOR 1.23, 95% CI 0.52-2.20, p = .7), or postoperative UTI (aOR 0.69, 95% CI 0.34-1.24, p = .2) controlling for age, body mass index, American Society of Anesthesiologists Physical Status class, tobacco use, diabetes, blood transfusion, operative time, inpatient versus outpatient procedure, race, and presence of endometriosis. CONCLUSION: After controlling for baseline comorbidities and surgical complexity, concomitant hysteroscopy with laparoscopic myomectomy does not significantly increase 30-day rates of SSIs or postoperative UTIs.
引用
- Najor AJ, Thappa S, Lee EM, et al. Infectious Morbidity Risk of Laparoscopic Myomectomy Concomitant Hysteroscopy: A National Surgical Quality Improvement Program (NSQIP) Analysis. J Minim Invasive Gynecol. 2026. PMID: 41864607. doi:10.1016/j.jmig.2026.03.010
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。